Cargando…
Immunological and Structural Characterization of Titin Main Immunogenic Region; I110 Domain Is the Target of Titin Antibodies in Myasthenia Gravis
Myasthenia gravis (MG) is an autoimmune disease caused by antibodies targeting the neuromuscular junction (NJ) of skeletal muscles. The major MG autoantigen is nicotinic acetylcholine receptor. Other autoantigens at the NJ include MuSK, LRP4 and agrin. Autoantibodies to the intra-sarcomeric striated...
Autores principales: | Stergiou, Christos, Williams, Rhys, Fleming, Jennifer R., Zouvelou, Vasiliki, Ninou, Elpinickie, Andreetta, Francesca, Rinaldi, Elena, Simoncini, Ornella, Mantegazza, Renato, Bogomolovas, Julius, Tzartos, John, Labeit, Siegfried, Mayans, Olga, Tzartos, Socrates |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9952892/ https://www.ncbi.nlm.nih.gov/pubmed/36830985 http://dx.doi.org/10.3390/biomedicines11020449 |
Ejemplares similares
-
Titin kinase is an inactive pseudokinase scaffold that supports MuRF1 recruitment to the sarcomeric M-line
por: Bogomolovas, Julijus, et al.
Publicado: (2014) -
Myasthenia Gravis: Autoantibody Specificities and Their Role in MG Management
por: Lazaridis, Konstantinos, et al.
Publicado: (2020) -
Titin kinase ubiquitination aligns autophagy receptors with mechanical signals in the sarcomere
por: Bogomolovas, Julius, et al.
Publicado: (2021) -
Immunotherapies in MuSK-positive Myasthenia Gravis; an IgG4 antibody-mediated disease
por: Vakrakou, Aigli G., et al.
Publicado: (2023) -
Autoantibody Specificities in Myasthenia Gravis; Implications for Improved Diagnostics and Therapeutics
por: Lazaridis, Konstantinos, et al.
Publicado: (2020)